Skip to content
    PETS
    Earnings call· Jun 2026(Q1 FY27)

    PETMED EXPRESS Q1 FY27 earnings call PETS

    Aug 13, 2026 Source

    Executive summary

    PetMed Express Q1 FY27 — Net Loss Narrows, Customer Acquisition Improves

    PetMed Express continued its operational and financial transformation in Q1 FY27, narrowing its net loss significantly due to cost management and the absence of a prior-year impairment charge. The company focused on diversifying customer acquisition, improving efficiency through technology upgrades, and strengthening its balance sheet via a planned sale-leaseback, while navigating a competitive pet health landscape and evaluating an unsolicited acquisition proposal.

    Highlights

    4

    • Net loss narrowed significantly to $6.1 million, down from $34.2 million in the prior year.

    • Cost of acquiring a new customer (CAC) reduced by 15% to $60 in Q1 FY27.

    • Recurring net sales grew to 61.5% of total gross sales, up from 57.6% year-over-year.

    • Acquired approximately 70,000 new customers in the quarter.

    Concerns

    3

    • Net sales declined 19.9% year-over-year to $41 million due to continued softness in prescription medication sales.

    • Adjusted EBITDA loss widened to $3.4 million from $2.7 million in the prior year.

    • Gross profit as a percentage of sales slightly declined to 27.6% from 28.1% year-over-year.

    Operational metrics

    13
    Net sales growth
    -19.9%YoY
    Q1 FY27

    Net sales were $41 million compared to $51.2 million in the same period last year, reflecting continued softness in prescription medication sales, partially offset by lower consumer promotional usage. This represents a third consecutive quarter of revenue stabilization above $40 million.

    Gross profit margin
    27.6%down from 28.1% YoY
    Q1 FY27

    Gross profit was $11.3 million compared to $14.4 million last year. The decline in margin primarily reflects lower manufacturer rebates as a percentage of sales, partially offset by lower freight costs per order.

    General and administrative expenses growth
    -13.5%YoY
    Q1 FY27

    General and administrative expenses were $11.2 million compared to $12.9 million last year, driven by lower professional fees, share-based compensation, and severance costs.

    Advertising expenses growth
    -30.2%YoY
    Q1 FY27

    Advertising expenses were $4.2 million compared to $6 million last year, reflecting lower gross media spend and the elimination of unproductive media.

    Depreciation and amortization
    $2.1Mvs $2.3M in Q1 FY26
    Q1 FY27

    Depreciation and amortization was $2.1 million compared to $2.3 million in the prior year period.

    Net loss per diluted share
    $0.28vs $1.65 in Q1 FY26
    Q1 FY27

    Net loss for the first quarter was $6.1 million compared to $34.2 million for the same period last year. This decrease was primarily driven by the absence of last year's goodwill and trade name impairment charge, and to a lesser extent, lower general and administrative and advertising expenses, partially offset by lower gross profit.

    Adjusted EBITDA loss
    $3.4Mvs loss of $2.7M in Q1 FY26
    Q1 FY27

    Adjusted EBITDA loss was $3.4 million compared to a loss of $2.7 million in the prior year.

    Recurring net sales as % of total gross sales
    61.5%up from 57.6% YoY
    Q1 FY27

    Includes AutoShip and membership-related revenue, underscoring the strength of the subscription-driven customer base.

    New customers acquired
    70,000trending upward over the past several quarters
    Q1 FY27

    This metric has been trending upward over the past several quarters.

    Cost of acquiring new customer (CAC)
    $60down 15% from $71 YoY
    Q1 FY27

    This meaningful improvement was driven by ongoing advertising and media spend optimization, including the selective elimination of unproductive media spend and other strategic reductions in marketing costs.

    Cash and cash equivalents
    $13.1M
    as of June 30, 2026

    The company had $13.1 million in cash and cash equivalents.

    Debt
    No debt
    as of June 30, 2026

    The company had no debt.

    Freight agreement impact
    Mitigates proposed cost increases
    Q1 FY27

    A new freight agreement was entered into that both mitigates proposed cost increases from a previous carrier and provides faster and more trackable service.

    Industry KPIs

    5
    MetricValueDetails
    Sg a OPEX ratio—
    Gross margin drivers27.6%%
    Active customers nspac70,000customers
    Net debt to adjusted EBITDANo debt
    Distribution supply chain cost economicsMitigated proposed cost increases

    Product announcements

    1
    ProductTypeDetails
    Rural King co-branded online pharmacy offeringlaunch

    Deals & partnerships

    3
    SilverCape InvestmentsUnsolicited, non-binding, and conditional proposal to acquire all outstanding shares of the company's stock.$3 per share in cash

    The Board has not yet reached any determination regarding SilverCape's proposal, and there is no assurance that any transaction will result. The company does not intend to comment further unless and until it determines that additional disclosure is appropriate or required.

    Rural KingCo-branded online pharmacy offering, representing PetMeds' first large-scale white-label pharmacy program.

    Launched in July, this partnership provides Rural King's customers across more than 150 stores in 17 states with access to pet medications, prescription food, preventatives, and AutoShip services through a platform powered by PetMeds.

    Undisclosed buyerSale-leaseback of headquarters and distribution center buildings in Delray Beach, Florida.$37 million10-year lease with subsequent renewal options

    Under the agreement, PetMeds will lease back the portion of the property housing its offices and Florida distribution center. The transaction is subject to a due diligence period, negotiation of the definitive lease agreement, and other customary closing conditions.

    Risks & headwinds

    4
    Competitive pet health landscapeOngoing

    Intensely competitive

    Mitigation: Focus on enhancing shareholder value, optimizing capital allocation, streamlining cost structure, developing new revenue streams, improving customer retention, modernizing technology, and enhancing customer service.

    Softness in prescription medication salesQ1 FY27

    Reflected in 19.9% year-over-year net sales decline to $41 million.

    Mitigation: Diversifying customer acquisition funnel, strategic initiatives like white-label pharmacy offerings.

    Increasing advertising costsOngoing

    Traditional advertising and media channels continue to become more expensive.

    Mitigation: Diversifying customer acquisition funnel, optimizing advertising and media spend, selective elimination of unproductive, high-cost programs, resulting in a 15% reduction in CAC.

    Lower manufacturer rebatesQ1 FY27

    Lower manufacturer rebates as a percentage of sales, contributing to a slight decline in gross profit margin from 28.1% to 27.6%.

    Mitigation: Partially offset by lower freight costs per order.

    What to watch in Q2 FY27

    5

    Sale-Leaseback Transaction Closure

    Within 120 days from July 23, 2026
    CurrentDefinitive agreement signed for $37M
    TargetTransaction closure

    Why it matters

    Unlocks real estate value and provides significant financial flexibility for strategic investments.

    We expect this transaction to close within approximately 120 days from the date of the definitive agreement, subject to a due diligence period, negotiation of the definitive lease agreement, and other customary closing conditions.

    2 min read5 chapters

    Detailed Narrative

    01

    Operational and Technology Transformation

    PetMed Express completed a comprehensive process to upgrade its enterprise resource planning (ERP) system, successfully rolling out SAP enterprise-wide in May. This represents the completion of one of the largest elements of its technology transformation initiative. Additionally, a new call center platform was launched in June to handle customer inquiries and sales more efficiently, and a new fraud prevention system, launched in Q4, continues to protect the business. These initiatives aim to create a stronger foundation for a more scalable and efficient organization.

    02

    Customer Acquisition and Retention Initiatives

    The company is diversifying its customer acquisition funnel beyond traditional advertising, which is becoming more expensive. In Q1, PetMeds acquired approximately 70,000 new customers, a metric that has been trending upward. The cost of acquiring a new customer was reduced by 15% to $60, down from $71 in the same period last year, driven by marketing optimization. Recurring net sales, including AutoShip and membership-related revenue, grew to 61.5% of total gross sales, up from 57.6% a year ago, underscoring the strength of its subscription-driven customer base.

    03

    Strategic Partnerships and New Revenue Streams

    In July, PetMeds officially launched a new co-branded online pharmacy offering with Rural King, providing customers across more than 150 stores in 17 states access to pet medications and services through a platform powered by PetMeds. This partnership is the company's first large-scale white-label pharmacy program and is seen as an important proof point for efficiently growing customer acquisition reach and developing new revenue streams. The company looks forward to announcing extensions of this white-label offering to additional partners.

    04

    Capital Allocation and Balance Sheet Optimization

    On July 23, PetMeds announced a definitive agreement for a sale-leaseback of its headquarters and distribution center buildings in Delray Beach, Florida, for an aggregate purchase price of $37 million. The company will lease back a portion of the property under a 10-year lease with renewal options. This transaction, expected to close within approximately 120 days, is intended to sharpen focus on the core pharmacy business, strengthen the balance sheet, and unlock real estate value, providing additional financial flexibility.

    05

    Unsolicited Acquisition Proposal and CEO Search

    PetMeds acknowledged receipt of an unsolicited, non-binding, and conditional proposal from SilverCape Investments to acquire all outstanding shares for $3 per share in cash. The Board has not yet reached a determination regarding this proposal. Separately, the Board is continuing its search for a permanent CEO with the assistance of a global executive search firm, prioritizing a candidate committed to driving long-term shareholder value and sustainable profitability.

    AI-generated summary of the company’s earnings call. Not investment advice.